Close

Tyme Technologies (TYME) Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results

Go back to Tyme Technologies (TYME) Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results

TYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating Results

February 4, 2021 8:00 AM EST

Announced Richie Cunningham as new Chief Executive Officer Presented data from TYME-88-Panc Study at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium Continued enrolling patients in multicenter randomized controlled TYME-88-Panc pivotal trial evaluating oral SM-88 as a potential treatment for third-line pancreatic cancer; full enrollment not expected before calendar year 2022 PanCAN enrolling patients in multicenter Precision Promise adaptive randomized Phase II/III registration-intent trial evaluating oral SM-88 as second-line monotherapy for pancreatic cancer Continued enrolling patients in Joseph Ahmed Foundations HopES Sarcoma investigator-initiated Phase II trial studying oral SM-88 as... More